The Effect of 0.12% Unoprostone Isopropyl (Rescula) on Intraocular Pressure in Normotensive Dogs

Ron Ofri, Dorit Raz, Philip H Kass, George N. Lambrou, Christine L. Percicot

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Rescula (0.12% unoprostone isopropyl) is the first docosanoid compound approved for treatment of glaucoma in humans. It is commercially available in Japan, and is undergoing clinical testing elsewhere. The aim of this study was to evaluate the effect of Rescula on intraocular pressure (IOP) in normotensive dogs. After establishing a baseline diurnal IOP curve, six dogs were unilaterally treated with Rescula while the contralateral eye was treated with a placebo. Applanation tonometry was performed in both eyes, and pupil size was evaluated, 30 min after treatment, and at 1-hr intervals for the next 9 hr. Rescula caused a significant (p=0.014) and long-lasting decrease in IOP, from 20.49 ± 2.02 mm Hg in control eyes to 15.49 ± 0.69 mm Hg in treated eyes. These results suggest that Rescula is potentially efficacious in treatment of canine glaucoma.

Original languageEnglish (US)
Pages (from-to)1313-1315
Number of pages3
JournalJournal of Veterinary Medical Science
Volume62
Issue number12
StatePublished - Dec 2000

Fingerprint

Intraocular Pressure
eyes
Dogs
glaucoma
dogs
Glaucoma
placebos
students
Manometry
Japan
Pupil
isopropyl unoprostone
Dog
Canidae
Therapeutics
Placebos
testing

Keywords

  • Canine
  • Glaucoma
  • Unoprostone isopropyl

ASJC Scopus subject areas

  • Marketing
  • veterinary(all)

Cite this

The Effect of 0.12% Unoprostone Isopropyl (Rescula) on Intraocular Pressure in Normotensive Dogs. / Ofri, Ron; Raz, Dorit; Kass, Philip H; Lambrou, George N.; Percicot, Christine L.

In: Journal of Veterinary Medical Science, Vol. 62, No. 12, 12.2000, p. 1313-1315.

Research output: Contribution to journalArticle

Ofri, Ron ; Raz, Dorit ; Kass, Philip H ; Lambrou, George N. ; Percicot, Christine L. / The Effect of 0.12% Unoprostone Isopropyl (Rescula) on Intraocular Pressure in Normotensive Dogs. In: Journal of Veterinary Medical Science. 2000 ; Vol. 62, No. 12. pp. 1313-1315.
@article{027c986a85e44389831f183c6e794a9c,
title = "The Effect of 0.12{\%} Unoprostone Isopropyl (Rescula) on Intraocular Pressure in Normotensive Dogs",
abstract = "Rescula (0.12{\%} unoprostone isopropyl) is the first docosanoid compound approved for treatment of glaucoma in humans. It is commercially available in Japan, and is undergoing clinical testing elsewhere. The aim of this study was to evaluate the effect of Rescula on intraocular pressure (IOP) in normotensive dogs. After establishing a baseline diurnal IOP curve, six dogs were unilaterally treated with Rescula while the contralateral eye was treated with a placebo. Applanation tonometry was performed in both eyes, and pupil size was evaluated, 30 min after treatment, and at 1-hr intervals for the next 9 hr. Rescula caused a significant (p=0.014) and long-lasting decrease in IOP, from 20.49 ± 2.02 mm Hg in control eyes to 15.49 ± 0.69 mm Hg in treated eyes. These results suggest that Rescula is potentially efficacious in treatment of canine glaucoma.",
keywords = "Canine, Glaucoma, Unoprostone isopropyl",
author = "Ron Ofri and Dorit Raz and Kass, {Philip H} and Lambrou, {George N.} and Percicot, {Christine L.}",
year = "2000",
month = "12",
language = "English (US)",
volume = "62",
pages = "1313--1315",
journal = "Journal of Veterinary Medical Science",
issn = "0916-7250",
publisher = "Japanese Society of Veterinary Science",
number = "12",

}

TY - JOUR

T1 - The Effect of 0.12% Unoprostone Isopropyl (Rescula) on Intraocular Pressure in Normotensive Dogs

AU - Ofri, Ron

AU - Raz, Dorit

AU - Kass, Philip H

AU - Lambrou, George N.

AU - Percicot, Christine L.

PY - 2000/12

Y1 - 2000/12

N2 - Rescula (0.12% unoprostone isopropyl) is the first docosanoid compound approved for treatment of glaucoma in humans. It is commercially available in Japan, and is undergoing clinical testing elsewhere. The aim of this study was to evaluate the effect of Rescula on intraocular pressure (IOP) in normotensive dogs. After establishing a baseline diurnal IOP curve, six dogs were unilaterally treated with Rescula while the contralateral eye was treated with a placebo. Applanation tonometry was performed in both eyes, and pupil size was evaluated, 30 min after treatment, and at 1-hr intervals for the next 9 hr. Rescula caused a significant (p=0.014) and long-lasting decrease in IOP, from 20.49 ± 2.02 mm Hg in control eyes to 15.49 ± 0.69 mm Hg in treated eyes. These results suggest that Rescula is potentially efficacious in treatment of canine glaucoma.

AB - Rescula (0.12% unoprostone isopropyl) is the first docosanoid compound approved for treatment of glaucoma in humans. It is commercially available in Japan, and is undergoing clinical testing elsewhere. The aim of this study was to evaluate the effect of Rescula on intraocular pressure (IOP) in normotensive dogs. After establishing a baseline diurnal IOP curve, six dogs were unilaterally treated with Rescula while the contralateral eye was treated with a placebo. Applanation tonometry was performed in both eyes, and pupil size was evaluated, 30 min after treatment, and at 1-hr intervals for the next 9 hr. Rescula caused a significant (p=0.014) and long-lasting decrease in IOP, from 20.49 ± 2.02 mm Hg in control eyes to 15.49 ± 0.69 mm Hg in treated eyes. These results suggest that Rescula is potentially efficacious in treatment of canine glaucoma.

KW - Canine

KW - Glaucoma

KW - Unoprostone isopropyl

UR - http://www.scopus.com/inward/record.url?scp=0034573784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034573784&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 1313

EP - 1315

JO - Journal of Veterinary Medical Science

JF - Journal of Veterinary Medical Science

SN - 0916-7250

IS - 12

ER -